株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

不死化細胞株の世界市場:将来予測

Global Immortalized Cell Line Market Research Report - Forecast to 2023

発行 Market Research Future 商品コード 711688
出版日 ページ情報 英文 126 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.72円で換算しております。
Back to Top
不死化細胞株の世界市場:将来予測 Global Immortalized Cell Line Market Research Report - Forecast to 2023
出版日: 2018年08月21日 ページ情報: 英文 126 Pages
概要

当レポートでは、世界の不死化細胞株の市場について分析し、製品の概要や市場の基本構造、主な市場促進・抑制要因、全体的な市場動向の見通し (今後7年間分)、手法別・用途別・エンドユーザー別・地域別の詳細動向、市場競争環境、主要企業のプロファイル・市場シェアなどを調査しております。

第1章 序論

第2章 エグゼクティブ・サマリー

第3章 市場概略

第4章 分析手法

第5章 市場のダイナミクス

  • イントロダクション
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第6章 市場要因の分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
    • 研究開発 (R&D)
    • 製造
    • 流通・販売
    • アフターセールス・モニタリング
  • 投資機会
  • 価格動向の分析

第7章 世界の不死化細胞株市場:手法別

  • 概要
    • ウイルス誘導
    • hHERT (ヒトテロメラーゼ逆転写酵素) の発現系
    • がん抑制遺伝子の不活性化
    • その他

第8章 世界の不死化細胞株市場:用途別

  • 概要
    • 診断
    • 創薬
    • ワクチン生産
    • 組織エンジニアリング・再生医療
    • その他

第9章 世界の不死化細胞株市場:エンドユーザー別

  • 概要
    • イントロダクション
    • 製薬/バイオテクノロジー企業
    • CRO (開発業務受託機関)
    • 研究所
  • 第10章 世界の不死化細胞株市場:地域別
  • 概要
  • 南北アメリカ
    • 北米 (米国、カナダ)
    • 南米
  • 欧州
    • 西欧 (ドイツ、フランス、英国、イタリア、スペインなど)
    • 東欧
  • アジア太平洋地域 (日本、中国、インド、オーストラリア、韓国など)
  • 中東・アフリカ

第11章 企業環境

  • 企業別市場シェアの分析
  • 競争環境
  • 主な動向

第12章 企業プロファイル

  • Thermo Fisher Scientific
    • 企業概略
    • 製品概要
    • 財務分析
    • 近年の主な動き
    • SWOT分析
    • 主要戦略
  • ATCC (American Type Culture Collection Inc.)
  • Valneva
  • Sartorius AG
  • Lonza Group, AG
  • Merck KGaA
  • Selexis SA
  • Wuxi App Tec
  • European Collection of Authenticated Cell Cultures (ECACC)
  • Corning Incorporated

第13章 付録

図表

List of Tables

  • TABLE 1 MARKET SYNOPSIS
  • TABLE 2 LIST OF ASSUMPTIONS
  • TABLE 3 GLOBAL IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 4 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 5 GLOBAL IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 6 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY REGION 2015-2023 (USD MILLION)
  • TABLE 7 GLOBAL IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY REGION 2015-2023 (USD MILLION)
  • TABLE 8 GLOBAL IMMORTALIZED CELL LINE MARKET FOR INACTIVATION OF TUMOUR SUPPRESSION GENES, BY REGION 2015-2023 (USD MILLION)
  • TABLE 9 GLOBAL IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 10 GLOBAL IMMORTALIZED CELL LINE MARKET FOR DIAGNOSTICS, BY REGION 2015-2023 (USD MILLION)
  • TABLE 11 GLOBAL IMMORTALIZED CELL LINE MARKET FOR DRUG DISCOVERY, BY REGION 2015-2023 (USD MILLION)
  • TABLE 12 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VACCINE PRODUCTION, BY REGION 2015-2023 (USD MILLION)
  • TABLE 13 GLOBAL IMMORTALIZED CELL LINE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION 2015-2023 (USD MILLION)
  • TABLE 14 GLOBAL IMMORTALIZED CELL LINE MARKET, BY END-USERS 2015-2023 (USD MILLION)
  • TABLE 15 GLOBAL IMMORTALIZED CELL LINE MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION 2015-2023 (USD MILLION)
  • TABLE 16 GLOBAL IMMORTALIZED CELL LINE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION 2015-2023 (USD MILLION)
  • TABLE 17 GLOBAL IMMORTALIZED CELL LINE MARKET FOR RESEARCH LABORATORIES, BY REGION 2015-2023 (USD MILLION)
  • TABLE 18 GLOBAL IMMORTALIZED CELL LINE MARKET, BY REGION 2015-2023 (USD MILLION)
  • TABLE 19 GLOBAL IMMORTALIZED CELL LINE MARKET, BY REGION 2017 & 2023 (USD MILLION)
  • TABLE 20 AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2015-2023 (USD MILLION)
  • TABLE 21 AMERICAS IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 22 AMERICAS IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 23 AMERICAS IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 24 AMERICAS IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 25 AMERICAS IMMORTALIZED CELL LINE MARKET, BY END-USERS 2015-2023 (USD MILLION)
  • TABLE 26 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY COUNTRY 2015-2023 (USD MILLION)
  • TABLE 27 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 28 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 29 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 30 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 31 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY END-USER 2015-2023 (USD MILLION)
  • TABLE 32 US IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 33 US IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 34 US IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 35 US IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 36 US IMMORTALIZED CELL LINE MARKET, BY END-USER 2015-2023 (USD MILLION)
  • TABLE 37 CANADA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USDMILLION)
  • TABLE 38 CANADA IMMORTALIZED CELL LINE MARKET FOR VIRCANADA INDUCTION, BY TYPE 2015-2023 (USDMILLION)
  • TABLE 39 CANADA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USDMILLION)
  • TABLE 40 CANADA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USDMILLION)
  • TABLE 41 CANADA IMMORTALIZED CELL LINE MARKET, BY END-USER 2015-2023 (USDMILLION)
  • TABLE 42 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 43 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET FOR VIRSOUTH AMERICA INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 44 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 45 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 46 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY END-USER 2015-2023 (USD MILLION)
  • TABLE 47 EUROPE IMMORTALIZED CELL LINE MARKET, BY REGION 2015-2023 (USD MILLION)
  • TABLE 48 EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 49 EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 50 EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 51 EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 52 EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 53 WESTERN EUROPE: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 54 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 55 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 56 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 57 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 58 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 59 GERMANY IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 60 GERMANY IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 61 GERMANY IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 62 GERMANY IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 63 GERMANY IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 64 FRANCE IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 65 FRANCE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 66 FRANCE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 67 FRANCE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 68 FRANCE IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 69 UK IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 70 UK IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 71 UK IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 72 UK IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 73 UK IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 74 ITALY IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 75 ITALY IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 76 ITALY IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 77 ITALY IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 78 ITALY IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 79 SPAIN IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 80 SPAIN IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 81 SPAIN IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 82 SPAIN IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 83 SPAIN IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 84 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 85 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 86 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 87 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 88 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 89 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 90 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 91 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 92 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 93 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 94 ASIA-PACIFIC: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 95 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 96 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 97 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 98 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 99 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 100 JAPAN IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 101 JAPAN IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 102 JAPAN IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 103 JAPAN IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 104 JAPAN IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 105 CHINA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 106 CHINA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 107 CHINA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 108 CHINA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 109 CHINA IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 110 INDIA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 111 INDIA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 112 INDIA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 113 INDIA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 114 INDIA IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 115 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 116 SOUTH KOREA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 117 SOUTH KOREA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 118 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 119 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 120 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 121 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 122 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 123 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 124 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 125 MIDDLE EAST AND AFRICA: IMMORTALIZED CELL LINE MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 126 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 127 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 128 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 129 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 130 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 131 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 132 MIDDLE EAST IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 133 MIDDLE EAST IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 134 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 135 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 136 AFRICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2015-2023 (USD MILLION)
  • TABLE 137 AFRICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 138 AFRICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2015-2023 (USD MILLION)
  • TABLE 139 AFRICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2015-2023 (USD MILLION)
  • TABLE 140 AFRICA IMMORTALIZED CELL LINE MARKET, BY END USERS 2015-2023 (USD MILLION)
  • TABLE 141 GLOBAL IMMORTALIZED CELL LINE MARKET: KEY DEVELOPMENT

List of Figures

  • FIGURE 1 GLOBAL IMMORTALIZED CELL LINE MARKET: MARKET STRUCTURE
  • FIGURE 2 RESEARCH PROCESS OF MRFR
  • FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 4 PORTERS FIVE FORCES ANALYSIS OF GLOBAL IMMORTALIZED CELL LINE MARKET
  • FIGURE 5 SUPPLY CHAIN: GLOBAL IMMORTALIZED CELL LINE MARKET
  • FIGURE 6 GLOBAL IMMORTALIZED CELL LINE MARKET, BY METHOD 2017 & 2023 (USD MILLION)
  • FIGURE 7 GLOBAL IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2017 & 2023 (USD MILLION)
  • FIGURE 8 GLOBAL IMMORTALIZED CELL LINE MARKET, BY END-USERS 2017 & 2023 (USD MILLION)
  • FIGURE 9 AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2017 (%)
  • FIGURE 10 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2017 (%)
  • FIGURE 11 EUROPE: IMMORTALIZED CELL LINE MARKET SHARE, BY REGION, 2017 (% SHARE)
  • FIGURE 12 WESTERN EUROPE: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2017 (%)
  • FIGURE 13 ASIA-PACIFIC: IMMORTALIZED CELL LINE MARKET SHARE, BY COUNTRY, 2017 (%)
  • FIGURE 14 MIDDLE EAST AND AFRICA: IMMORTALIZED CELL LINE MARKET SHARE, BY REGION, 2017 (%)
  • FIGURE 15 GLOBAL IMMORTALIZED CELL LINE MARKET, MARKET SHARE ANALYSIS 2017 (%)
  • FIGURE 16 GLOBAL IMMORTALIZED CELL LINE MARKET COMPETITIVE LANDSCAPE (%)
目次

Introduction

Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. HepaRG and Hep G2 cell lines are most frequently used for toxicity studies among the currently available human hepatic cell lines.

The immortalized cell line plays a vital role in cell biology while studying multicellular organisms and their biochemistry. The demand for immortalized cell lines is increasing and so as the applications. The increasing adoption of immortalized cell lines in stem cell therapy drives the growth of the market.

Besides, the increasing awareness regarding the use of cell lines in healthcare, rising vaccines production, increasing application of cell lines in cancer therapy, and use of innovative technology for cell lines have fueled the growth of the market. On the other hand, the high cost of equipment and difficulties in developing a stable and authentic strain have restrained the growth of the immortalized cell line market.

Moreover, continuous cell lines are widely used by numerous pharmaceutical and biotech-based companies as a specimen for testing the drug efficacy. Due to this, there is a reduction in the use of gnotobiotic animals such as mice, rabbits, and monkeys, among others. Moreover, as these cell lines have a long shelf life and can be easily preserved via cryopreservation and lyophilization techniques, several biotech and pharmaceutical companies are preferring them over other media cultures for performing their R&D activities. For instance, as per a report published by the Department of Pharmaceutical Sciences and Bio Manufacturing Research Institute and Technology Enterprises (BRITE), in 2014, around 1.3 USD billion capital was invested in new pharmaceuticals for drug discovery through cell line culture.

The global immortalized cell line market is segmented based on method, application, and end-user.

Based on method, the market is further segmented into virus induction, HTERT expression, inactivation of tumor, suppression genes, and others.

Based on application, the market is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.

Based on end-user, the market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, and research laboratories.

The global immortalized cell line market was valued at USD 2,421.34 million in 2017 and is expected to register a CAGR of 9.30% during the forecast period from 2018 to 2023.

Key Players

Lonza Group AG, Corning Incorporated, Thermo Fisher Scientific, Selexis SA, Valneva, European Collection of Authenticated Cell Cultures (ECACC), Sartorius AG, ATCC (American Type Culture Collection Inc.), Merck KGaA, and Wuxi App Tec, and others

Study objectives

To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global immortalized cell line market

  • To provide insights into factors influencing and affecting the market growth
  • To provide historical and forecast revenue of market segments and sub-segments with respect to countries
  • To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
  • To provide economic factors that influence the global immortalized cell line market
  • To provide a detailed analysis of the value chain and supply chain of the global immortalized cell line market

Target Audience

  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Key Findings

  • The global immortalized cell line market is expected to reach USD 4,105.62 million by 2023 at a CAGR of 9.30% from 2018 to 2023
  • On the basis of method, virus induction accounted for the largest market share of 39.9% in the year 2017 and was valued at USD 965.97 million in the same year
  • On the basis of application, diagnostic accounted for the largest market share of 32.1% in 2017
  • The Americas holds the largest share of the global immortalized cell line market which is expected to reach USD 1,505.38 million by 2023
  • Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 10.04 % from 2018 to 2023

Regional Analysis

  • Americas
    • North America
  • US
  • Canada
    • South America
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Republic of Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
    • Africa

Table of Contents

1 Report Prologue

2 Executive Summary

3 Market Introduction

  • 3.1 Scope of Study
  • 3.2 Research Objective
  • 3.3 List of Assumptions
  • 3.4 Market Structure

4 Research Methodology

  • 4.1 Research Process
  • 4.2 Primary Research
  • 4.3 Secondary Research
  • 4.4 Market Size Estimation
  • 4.5 Forecast Model

5 Market Dynamics

  • 5.1 Introduction
  • 5.2 Drivers
    • 5.2.1 Increasing application in biotech & pharmaceutical companies and hospitals
    • 5.2.2 Growing number of patients in need of organ transplantation
    • 5.2.3 Rise in the patient population affected by cancer
  • 5.3 Restraints
    • 5.3.1 High cost of equipment
    • 5.3.2 Developing stable and authentic cell lines
  • 5.4 Opportunities
    • 5.4.1 Entering untapped markets
    • 5.4.2 Increasing use of cell line culture in cancer and stem cell research

6 Market Factor Analysis

  • 6.1 Porters Five Forces Analysis
    • 6.1.1 Bargaining Power of Suppliers
    • 6.1.2 Bargaining Power of Buyers
    • 6.1.3 Threat of New Entrants
    • 6.1.4 Threat of Substitutes
    • 6.1.5 Intensity of Rivalry
  • 6.2 Supply chain analysis
    • 6.2.1 R&D
    • 6.2.2 Manufacturing
    • 6.2.3 Distribution & Sales
    • 6.2.4 Post-Sales Monitoring
  • 6.3 Investment Opportunities
  • 6.4 Pricing Analysis

7 Global Immortalized Cell Line Market, by Method

  • 7.1 Overview
    • 7.1.1 Virus Induction
    • 7.1.2 HTERT Expression
    • 7.1.3 Inactivation of Tumour Suppression Genes
    • 7.1.4 Others

8 Global Immortalized Cell Line Market, by Application

  • 8.1 Overview
    • 8.1.1 Diagnostics
    • 8.1.2 Drug Discovery
    • 8.1.3 Vaccine Production
    • 8.1.4 Tissue Engineering and Regenerative Medicines
    • 8.1.5 Others

9 Global Immortalized Cell Line Market, by End-user

  • 9.1 Overview
    • 9.1.1 Introduction
    • 9.1.2 Pharmaceutical and Biopharmaceutical Companies
    • 9.1.3 Contract Research Organizations
    • 9.1.4 Research Laboratories

10 Global Immortalized Cell Line Market, By Region

  • 10.1 Overview
  • 10.2 Americas
    • 10.2.1 North America
      • 10.2.1.1 US
      • 10.2.1.2 Canada
    • 10.2.2 South America
  • 10.3 Europe
    • 10.3.1 Western Europe
      • 10.3.1.1 Germany
      • 10.3.1.2 France
      • 10.3.1.3 UK
      • 10.3.1.4 Italy
      • 10.3.1.5 Spain
      • 10.3.1.6 Rest of Western Europe
    • 10.3.2 Eastern Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 South Korea
    • 10.4.5 Rest of Asia-Pacific
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East
    • 10.5.2 Africa

11 Competitive Landscape

  • 11.1 Company Market Share Analysis
    • 11.1.1 Introduction
  • 11.2 Competitive Landscape
    • 11.2.1 Introduction
  • 11.3 Key Developments

12 Company Profiles

  • 12.1 Thermo Fisher Scientific
    • 12.1.1 Company Overview
    • 12.1.2 Financial Overview
    • 12.1.3 Products Offering
    • 12.1.4 Key Developments
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Strategy
  • 12.2 ATCC (American Type Culture Collection Inc.)
    • 12.2.1 Company Overview
    • 12.2.2 Financial Overview
    • 12.2.3 Products Offering
    • 12.2.4 Key Developments
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Strategy
  • 12.3 Valneva
    • 12.3.1 Company Overview
    • 12.3.2 Financial Overview
    • 12.3.3 Products Offering
    • 12.3.4 1.3.4 Key Developments
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Strategy
  • 12.4 Sartorius AG
    • 12.4.1 Company Overview
    • 12.4.2 Financial Overview
    • 12.4.3 Products Offering
    • 12.4.4 Key Developments
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Strategy
  • 12.5 Lonza Group, AG
    • 12.5.1 Company Overview
    • 12.5.2 Financial Overview
    • 12.5.3 Products Offering
    • 12.5.4 Key Developments
    • 12.5.5 Swot Analysis
    • 12.5.6 Key Strategy
  • 12.6 Merck KGaA
    • 12.6.1 Company Overview
    • 12.6.2 Financial Overview
    • 12.6.3 Products Offering
    • 12.6.4 Key Developments
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Strategy
  • 12.7 Selexis SA
    • 12.7.1 Company Overview
    • 12.7.2 Financial Overview
    • 12.7.3 Products Offering
    • 12.7.4 Key Developments
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Strategy
  • 12.8 Wuxi App Tec
    • 12.8.1 Company Overview
    • 12.8.2 Financial Overview
    • 12.8.3 Products Offering
    • 12.8.4 Key Developments
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Strategy
  • 12.9 European Collection of Authenticated Cell Cultures (ECACC)
    • 12.9.1 Company Overview
    • 12.9.2 Financial Overview
    • 12.9.3 Products Offering
    • 12.9.4 Key Developments
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Strategy
  • 12.1 Corning Incorporated
    • 12.10.1 Company Overview
    • 12.10.2 Financial Overview
    • 12.10.3 Products Offering
    • 12.10.4 Key Developments
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Strategy

13 Appendix

  • 13.1 Discussion Blue Print
Back to Top